1. A Review of the Role of Type 2 Diabetes Mellitus and Sodium-Glucose Cotransporter-1 Inhibitors in Heart Failure With Preserved Ejection Fraction
- Author
-
Gladys I Palaguachi and William H. Frishman
- Subjects
Heart Failure ,medicine.medical_specialty ,Cardiovascular safety ,business.industry ,Sodium ,MEDLINE ,Stroke Volume ,General Medicine ,Type 2 diabetes ,medicine.disease ,Glucose ,Increased risk ,Diabetes Mellitus, Type 2 ,Heart failure ,Internal medicine ,medicine ,Cardiology ,Risk of mortality ,Humans ,Cardiology and Cardiovascular Medicine ,business ,Heart failure with preserved ejection fraction ,Cardiovascular outcomes - Abstract
Previous research has demonstrated that patients with Type 2 Diabetes (T2DM) are at an increased risk for cardiovascular events, including heart failure. Moreover, there's a higher risk of mortality in individuals who have both T2DM and heart failure with preserved ejection fraction (HFpEF). Although there are antidiabetic agents that have shown both cardiovascular safety and improved cardiovascular outcomes, only certain agents have been associated with heart failure benefits, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors. This study aims to review the pathophysiology of HFpEF in the setting of T2DM, and more specifically the role of SGLT2 inhibitors in HFpEF outcomes.
- Published
- 2021
- Full Text
- View/download PDF